Research found that two selective HDAC6 inhibitors, tubastatin A and ACY-1215, could improve microtubule stability and ameliorate cognitive impairment in AD mouse by promoting tubulin acetylation, reducing production of Aβ and hyper-phosphorylated tau and facilitating autophagic clearance of Aβ and hyper-phosphorylated tau [25]. This evidence concerns the gene MAPT and Cognitive impairment.